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The human intestinal tract harbors large bacterial community consisting of commensal, 
symbiotic, and pathogenic strains, which are constantly interacting with the intestinal 
immune system. This interaction elicits a non-pathological basal level of immune 
responses and contributes to shaping both the intestinal immune system and bacterial 
community. Recent studies on human microbiota are revealing the critical role of intes-
tinal bacterial community in the pathogenesis of both systemic and intestinal diseases, 
including Crohn’s disease (CD). NOD2 plays a key role in the regulation of microbiota 
in the small intestine. NOD2 is highly expressed in ileal Paneth cells that provide critical 
mechanism for the regulation of ileal microbiota through the secretion of anti-bacterial 
compounds. Genome mapping of CD patients revealed that loss of function mutations 
in NOD2 are associated with ileal CD. Genome-wide association studies further demon-
strated that NOD2 is one of the most critical genetic factor linked to ileal CD. The bacterial 
community in the ileum is indeed dysregulated in Nod2-deficient mice. Nod2-deficient 
ileal epithelia exhibit impaired ability of killing bacteria. Thus, altered interactions between 
ileal microbiota and mucosal immunity through NOD2 mutations play significant roles in 
the disease susceptibility and pathogenesis in CD patients, thereby depicting NOD2 as 
a critical regulator of ileal microbiota and CD.
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NOD2, A MeMBeR OF THe NLR FAMiLY, ReGULATeS iNNATe 
AND ADAPTive iMMUNe ReSPONSeS
NLR [Nucleotide binding domain (NBD)-leucine rich repeats (LRR) containing or nucleotide-
binding oligomerization domain (NOD)-like receptor] proteins play an important role in shaping 
the immune system. Humans have 22 NLR protein members and mice have 34 members whereby 
abundance may vary in relation to cell types (1–4). While certain NLR protein members are criti-
cal for the early embryogenesis (5, 6) or upregulation of major histocompatibility complex (MHC) 
molecules (4, 7–10), other group of NLR proteins have important roles in recognizing pathogen and 
damage-associated molecular patterns (PAMPs and DAMPs, respectively) in the cytoplasm and elic-
iting innate immune responses (1, 11–16). NLRs have a tripartite structure consisting of an amino-
terminal effector domain, a central NBD, and a carboxy-terminal LRR (17). Most NLR proteins 
contain distinct protein–protein association domains, such as caspase recruitment domain (CARD), 
pyrin domain (PYD), or a baculovirus inhibitor repeat (BIR). These variations of the amino-terminal 
domain are used to categorize NLRs into major subfamilies, which include NLRCs (NLRs containing 
CARD), NLRPs (NLRs containing Pyrin), and others (1, 3, 11, 14, 18–20). The central NBD, found 
in all NLRs, is involved in oligomerization and activation (1, 3). The carboxy-terminal LRRs may be 
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used for the recognition of PAMPs and DAMPs by many NLRs, 
except NLRP4 and NAIP (Neuronal Inhibitor Apoptosis Protein) 
that do not use LRRs for ligand recognition (1, 3, 20–24).
NOD2 is a 110 kDa cytosolic protein (1040 amino acids) with 
two CARD domains, thereby is a part of the NLRC subfamily 
(13, 15). Known as a major genetic risk factor for Crohn’s disease 
(CD), NOD2 gene is located on human chromosome 16p21. 
Upstream of the transcription start site of NOD2, are two NF-κB-
binding sites within the promoter at 26 and 301  bp as well as 
vitamin D receptor-binding sites within the NOD2 gene (25–27). 
NOD2 is highly expressed in myeloid cells, such as dendritic 
cells and macrophages, but expression is low in T cells (27–30). 
Furthermore, NOD2 is highly expressed in Paneth cells in the 
ileum with a lesser degree in epithelial cells from the intestines, 
oral cavity, and lungs (28, 29, 31–33). NOD2 expression is induced 
by bacterial components (e.g., LPS), short-chain fatty acids (e.g., 
butyrate), hormonal vitamin D (1,25-dihydroxyvitamin D3), and 
pro-inflammatory cytokines (e.g., TNF-α) (25, 27, 28, 34–39). The 
expression of NOD2 and downstream kinase, receptor-interacting 
serine/threonine-protein kinase 2 (RIP2) in the intestine is largely 
dependent on the presence of gut microbiota as the expression of 
these two genes is significantly low in germ-free mice and can be 
restored by colonization of single strains of bacteria or microflora 
from mice under SPF conditions (28, 31, 35).
It has been shown that NOD2 recognizes muramyl dipeptide 
(MDP), N-acetylmuramyl-l-alanyl-d-isoglutamine (40–42). 
LRRs at C-terminus are responsible for direct recognition of 
MDP, although affinity is not strong for in vitro association assays 
(13, 15). MDP is derived from peptidoglycan found mainly in 
Gram-positive bacteria and to a lesser extent in Gram-negative 
bacteria. MDP can be transported into the cytoplasm of mam-
malian cells from endo/phagosome through transporters, such 
as solute carrier family protein 5 (SLC15A4) (43–45). Both MDP 
recognition and NOD2 oligomerization are enhanced when ATP 
binds to the Walker A motif in the NBD, known to regulate the 
activity of most NLRs (13, 15).
NOD2 activation promotes oligomerization and recruitment 
of RIP2 by CARD-CARD homophilic interactions (Figure 1) (36, 
46–48). E3 ligases [TNF receptor associated factor 6 (TRAF6), 
TNF receptor associated factor 2 (TRAF2), cellular inhibitor 
of apoptosis protein (cIAP2)] are recruited to this NOD2-RIP2 
platform to ubiquitinate NEMO (NF-κB essential modulator) at 
amino acid R285 and R399 (42, 47, 49, 50). Whereas NOD2 is 
subsequently ubiquitinated and undergoes proteasomal degra-
dation (51), TGFβ-activated kinase 1 (TAK1) and ubiquitinated 
NEMO form a complex within proximity to activate IκB kinase 
(IKK) that initiates the NF-κB signaling pathway (37, 46, 50). 
Once phosphorylated by IKK, IκB-α is targeted to proteasomal 
degradation that permits free NF-κB to translocate into the 
nucleus (35, 42, 46, 47, 50) (Figure 1).
In addition to NF-κB activation, the mitogen-activated 
protein kinases (MAPK), such as p38 and ERK, are activated 
in a TRAF6-dependent manner (42, 50) (Figure 1). Activation 
of these signaling cascades upon NOD2 stimulation induces 
the production of a variety of cytokines, chemokines, and 
antimicrobial peptides (TNF-α, IL-6, IFN-γ, IL-1β, IL-10, IL-8/
CXCL8, α-defensin) depending on cell types (30, 52). NOD2 
signal cascade is enhanced by toll-like receptor (TLR) agonists 
through NF-κB. Along with MDP, this relationship further 
highlights the impact of microbial components on the NOD2 
pathway (1, 30, 53).
Through the innate immune system, NOD2 provides a 
defensive strategy to protect the hosts against bacterial infection. 
Various epithelial cells throughout the human body not only 
create a physical barrier but also produce antimicrobial peptides 
to regulate bacterial colonization (29, 31, 54). In addition to 
NOD2 gene, mutations in ATG16L1 (Autophagy-related 16 Like 
1) gene are a risk factor for CD (55). ATG16L1 is a component 
of a large protein complex essential for autophagy, a mechanism 
that degrades intracellular components using the lysosome. As 
NOD2 is capable of recruiting ATG16L1 to the plasma mem-
brane at the bacterial entry site, NOD2 mutants failed to recruit 
ATG16L1, ultimately impairing autophagosomal encapsulation 
of invading bacteria in dendritic cells (56, 57). Therefore, both 
ATGL16 and NOD2 have interrelated roles for regulating the 
microbial invasion that has yet to be studied in Paneth cells 
(Figure  1). However, in Paneth cells, NOD2 recruitment onto 
dense vesicles helps coordinate cargo-sorting events that sup-
port host defenses (58). Therefore, NOD2 function and related 
responses regulate interactions between innate immunity and 
the intestinal microbiota.
As noted above, NOD2 and TLR signaling cooperate to 
enhance immune responses. This synergy of NOD2 and TLR 
activation affects the polarization of T cell adaptive immunity 
(Th1 vs. Th2 immune responses) (42, 52, 59, 60). While it is well 
documented that the NOD2 pathway cooperates with signals 
through NOD1 or various TLRs (e.g., TLR3, TLR4, TLR9) to 
enhance Th1 immune responses, Th2 responses are also induced 
through the cooperation of NOD2 with TLR2 agonists (35, 
52, 61, 62). Regarding humoral immunity, NOD2 is capable of 
influencing antigen-specific immunoglobulin production based 
on studies using Nod2-deficient mice (42, 52). Thus, NOD2 
expression impacts immune responses as well as bacterial kill-
ing and colonization in the ileum (25, 31, 34, 35, 52, 61–63). In 
addition to bacterial components, dietary fiber as well as vitamin 
D-containing products also induces expression of NOD2 to fur-
ther increase the regulation of the microbiota (26, 28, 35).
eTiOLOGY AND PATHOPHYSiOLOGY OF 
CROHN’S DiSeASe
Crohn’s disease is a chronic, relapsing inflammatory disorder 
of the gastrointestinal tract, most commonly involving the 
ileum and colon. CD patients typically suffer from frequent and 
chronically relapsing flares with diarrhea, abdominal pain, rectal 
bleeding, and malnutrition. Histologically, CD is characterized 
by transmural infiltration of lymphocytes and macrophages with 
granuloma. Because of the clinical and histological features, most 
CD patients require lifelong treatment, such as medication and 
surgery. For efficient treatment of CD, it is important to identify 
patients who carry risk factors for complications of the disease 
and initiate appropriate therapy at early phase of the clinical 
course (64).
FiGURe 1 | NOD2 senses MDP and elicits immune responses. MDP-derived from bacterial cell wall can be transported into the cytosol by endo/phagosome 
through peptide transporters (e.g., SLC15A4). MDP activates NOD2 to initiate RIPK2 recruitment resulting in platform formation. This cytosolic NOD2-initiated 
structure localizes E3 ligases (e.g., TRAF6) to ubiquitinate NEMO, for which NEMO and TAK1 forms a complex near IKK. In addition to activating the mitogen-
activated protein kinase (MAPK) pathway, TAK1 phosphorylates IKK to initiate the NF-κB signaling pathway. IκB-α is phosphorylated by IKK, which targets IκB-α to 
proteasome degradation. No longer restricted, free NF-κB translocates into the nucleus and activates various immune response genes. NOD2 also recruits 
ATG16L1 near the plasma membrane to promote autophagosome formation, known to degrade antigenic structures. The release of cytokines and chemokines, 
initiated by NOD2, recruits immune cells to influence Th1 and Th2 responses.
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In the healthy human intestine, the intestinal epithelium 
provides an effective barrier against luminal bacteria with 
the help of epithelial tight junction and the mucus layer 
(Figure  2). However, in patients with inflammatory bowel 
diseases, this barrier function is often compromised due 
to genetic, environmental, microbial, and immunological 
factors (65, 66). Dysfunctional mucosal barrier allows the 
penetration of bacterial products, leading to direct interac-
tion with immune cells (Figure 2). Innate immune cells, such 
as macrophages and dendritic cells produce cytokines, such 
as TNF-α, IL-1β, IL-6, IL-12, IL-23, and chemokines upon 
recognition of microbes and microbial products. Activated 
dendritic cells promote the differentiation of CD4+ T cells 
into pro-inflammatory T cell subsets, such as Th1 or Th17 
effector T cells, which secrete additional cytokines and 
chemokines (65, 66). Recently identified novel family of 
innate immune cells termed innate lymphoid cells (ILCs), in 
particular the type 1 ILC (ILC1) subset, produce high amount 
of pro-inflammatory cytokines, such as IFN-γ and TNF-α 
(67–69). High levels of chemokines produced by these innate 
and adaptive immune cells further recruit lymphocytes, 
creating a vicious positive feedback cycle of inflammation 
in CD.
NOD2: THe HiGHeST RiSK FACTOR iN 
iLeAL CD
Recent Genome-wide association studies (GWAS) revealed 163 
susceptibility loci for IBD (inflammatory bowel disease), 30 of 
them being specific to CD (70). Among them, NOD2 was the first 
gene identified as a risk factor for ileal CD (71, 72), discovered 
by the genetic mapping study of the CD susceptibility locus (73). 
One of the cell types that express NOD2 at a high level is the 
Paneth cell, most of which are located in the terminal ileum (32). 
Paneth cells play an important role in the innate regulation of gut 
microbiota by synthesizing and secreting antimicrobial peptides 
or proteins. Upon the stimulation with bacterial products, such 
as the NOD2 ligand, MDP, Paneth cells secrete antimicrobial pep-
tides, including lysozyme, secretory phospholipase A2 (sPLA2), 
and human α-defensins 5 and 6 (HD5 and HD6) in the intestinal 
lumen (74). Therefore, NOD2 mutations lead to dysregulation 
of host–microbe interactions, which increases the susceptibility 
to abnormal ileal inflammation. In addition to this microbial 
dysbiosis, other genetic or environmental factors trigger the 
development of ileal CD.
A meta-analysis showed the risk for CD development was 
increased to 17.1-fold in NOD2 homozygotes or compound 
FiGURe 2 | NOD2-associated dysregulated microbiota leads to the susceptibility of CD. Ileum in healthy individuals (left panel). NOD2 senses microbiota-
derived MDP and activates NF-κB through the downstream kinase receptor-interacting protein 2 (RIP2), which is critical for the bacterial killing activity of Paneth 
cells via the secretion of anti-bacterial compounds. Ileum with loss of NOD2 function (right panel). In CD, that is associated with NOD2 mutations, CD-associated 
NOD2 mutants disturb many characteristics of gut immune homeostasis, including reduced MDP sensing, and impaired antimicrobial responses in Paneth cells, 
leading to defective bacterial clearance. This dysbiosis caused by impaired Paneth cell function is characterized by increased load of bacteria and abnormalities of 
Peyer’s patches (PP) and mesenteric lymph nodes (MLN) that stimulate the mucosal immune system to induce Th1 immune response, leading to chronic 
inflammation.
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heterozygotes, and 2.4-fold in simple NOD2 heterozygotes 
(Table  1) (75). Three main variants or polymorphisms in 
NOD2 gene (i) a frame shift mutation at position 1007 (1007fs); 
(ii) a glycine to arginine conversion at amino acid residue 
908 (G908R); and (iii) an arginine to tryptophan conversion 
at amino acid residue 702 (R702W) were highly associated 
with susceptibility to CD (71, 72, 76). All three mutations are 
located within or close to the LRR domain that recognizes MDP. 
Indeed, patients with ileal CD showed reduced levels of HD5 
and HD6 derived from Paneth cells (77, 78). Additionally, the 
production of α-defensins is particularly reduced in patients 
with non-functional NOD2 mutations (79, 80). These findings 
showed that CD-related mutations in NOD2 are loss of function 
and individuals carrying NOD2 mutations are at high risk for 
ileal CD.
Furthermore, many studies have suggested that NOD2 
mutations increase the risk of complications in CD (Table  1). 
It was shown that any of the NOD2 mutations are independ-
ent predictive factor for stricturing [odds ratio (OR) =  1.82], 
fistulizing (OR = 1.25), and need for surgery (OR = 2.96) (81). 
A meta-analysis reported that the risk for complicated disease, 
such as stricturing or fistulizing, was increased by 8% [relative 
risk (RR) = 1.08] in NOD2 heterozygotes and 41% (RR = 1.41) in 
NOD2 homozygotes or compound heterozygotes (82). Likewise, 
the risk of surgery was increased by 58% (RR = 1.58) with any of 
the NOD2 mutations (82). In terms of each risk allele, p.1007fs 
mutation is the strongest disease predictive factor. p.1007fs 
was associated with stricturing (OR =  1.38) and the necessity 
of an operation (OR  =  1.69) (83). The homozygous carriers 
of p.1007fs were significantly younger at the time of diagnosis 
(under the age of 26  years). Fourteen out of 19 homozygous 
carriers of p.1007fs (73.7%) required surgery and 11 out of 14 
patients (78.6%) underwent the re-operation due to re-stenosis 
(84). The mutation of p.G980R is also associated with disease 
complications [RR =  1.33 (82), OR =  1.65 (83)]. Interestingly, 
multiple studies indicated that association of NOD2 mutations 
with CD were found in European and Ashkenazi Jewish ancestry 
population, but not in CD patient cohort of Asian ancestry, such 
as Japanese, Chinese, Korean, or Indian, indicating the impact 
of ethnic genetic background on the CD susceptibility caused by 
NOD2 mutations (85–88).
Taken together, NOD2 mutation and the susceptibility of 
ileal CD are strongly related via altered interaction between 
ileal microbiota and mucosal immunity. Carrying the NOD2 
TABLe 1 | NOD2 mutations in CD patients.
Reference NOD2 mutation 
type
Risk for increase of risk
Economou 
et al. (75)
Single risk allelea Development of CD 2.39-fold (OR = 2.39)
Two or more risk 
allelesa
Development of CD 17.1-fold (OR = 17.1)
Cleynen 
et al. (81)
Any Nod2 
mutations
Ileal location 1.90-fold (OR = 1.90)
Stricturing 1.82-fold (OR = 1.82)
Fistulizing 1.25-fold (OR = 1.25)
Need for surgery 2.96-fold (OR = 2.96)
Adler et al. 
(82)
Single risk allelea Stricturing or 
fistulizing
8% (RR = 1.08)
Two risk allelesa Stricturing or 
fistulizing
41% (RR = 1.41)
Any risk allelesa Need for surgery 58% (RR = 1.58)
G980R Stricturing 33% (RR = 1.33)
Weersma 
et al. (83)
1007fs Ileal location 1.83-fold (OR = 1.83)
Stricturing 1.38-fold (OR = 1.38)
Need for surgery 1.69-fold (OR = 1.69)
G980R Stricturing 1.65-fold (OR = 1.65)
Seiderer 
et al. (84)
1007fs Early onset 73.7% (14/19 patients)
Re-operation 
(re-stenosis)
78.6% (11/14 patients)
aRisk allele: 1007fs, G908R or R702W.
OR, odds ratio; RR, relative risk.
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mutation is the strong risk factor for ileal CD with multiple 
complications.
ROLe OF MiCROBiOTA iN iLeAL CD
The surfaces of the body, particularly the gastrointestinal tract, 
are exposed to a large number of diverse microbes that are 
collectively referred to as the microbiota. Composition of the 
microbiota can be significantly affected by the genetic back-
ground of hosts along with several other factors, such as diet, 
age, stress, and diseases (89). While commensal bacteria colonize 
all mucosal surfaces and the skin, the intestinal tract harbors 
the largest bacterial load (up to 1014 total bacteria) (90, 91). It is 
becoming increasingly clear that the close symbiotic relationship 
between host and an adaptable microbiota forms a vital part of 
the intestinal homeostasis (92, 93). The host microbiota plays 
important roles in several processes such short-chain fatty acid 
production (94), the development of intestinal epithelium (95, 
96), protection against invading pathogens, and, importantly, 
the development of mature immune system (96). The intestinal 
microbiota provides both inflammatory and anti-inflammatory 
products, which modulate the immune responses (97, 98) and 
dysbiosis in the microbiota is considered pivotal to the origin 
of many diseases. It is well known that the disease outcome can 
be influenced by the host microbiota either due to the increased 
colonization of pathogenic strains or the introduction of new 
bacterial species. This is well-exemplified in IBD patients who 
typically exhibit imbalances in the microbiota composition. 
Moreover, reducing exposure to intestinal bacteria in these 
patients has been shown to frequently alleviate inflammation 
(99, 100).
ROLe OF NOD2 iN THe iNTeRACTiON 
BeTweeN MiCROBiOTA AND iLeAL HOST 
iMMUNiTY
NOD2 plays an important role in mediating host–microbe inter-
actions in the intestine. Interestingly, NOD2 has been shown to 
contribute to the homeostatic maintenance of the gut microbiota. 
Abnormal NOD2 function associated with LRR polymorphisms 
leads to an inflammatory response mediated by innate immune 
functions (42, 71, 72, 101). NOD2 controls the expression 
and secretion of antimicrobial peptides thereby acting as an 
important regulator of the ileal commensal microbiota in mice 
(31). Nod2-deficient mice exhibit reduced bactericidal activity, 
higher loads of commensal bacteria and increased susceptibility 
to colonization by pathogenic bacteria (31, 102), and are, thus, 
prone to bacterial infections and intestinal inflammation (30, 
42). NOD2 function, therefore, may be pivotal in understanding 
the balance between the host immune system and commensal 
bacteria.
NOD2-MeDiATeD ReGULATiON OF iLeAL 
MiCROBiOTA
NOD2 is critical for regulating the bacterial flora in the ileum 
through the secretion of anti-bacterial compounds (31, 42, 103–
105) (Figure 2). Earlier studies in Nod2-deficient mice indicated 
the role of NOD2 in the homeostasis of gut epithelium, possibly 
linking it to the development of CD (42). Furthermore, increased 
NOD2 expression is observed at the sites for α-defensin secretion, 
such as intestinal crypts in mice (42) and Paneth cells in human 
(32, 33). Nod2-deficient mice harbor larger loads of bacteria in 
the ileum due to impaired Paneth cell function, compared to lit-
termate controls even in the same cage (31). Nod2-deficient mice 
are susceptible to Th1-dominant granulomatous inflammation 
in the ileum, which is induced by an opportunistic pathogen 
Helicobacter hepaticus and ileal dysbiosis (2, 30). Furthermore, 
NOD2 expression in the intestine is regulated by signals from the 
microbiota, given that germ-free mice had lower NOD2 expres-
sion that was reversible upon monocolonization with commensal 
bacteria (31). Zhang et al. found that NOD2-mediated lysozyme 
trafficking in Paneth cells is directed by commensal bacteria, 
which is important for regulating intestinal infection (58). Two 
different steps, selective lysozyme trafficking and final secretion 
(106) are separately regulated by commensals implicating a new 
mechanism by which symbiotic bacteria direct a lysozyme-
trafficking event to promote host defense against pathogens.
Several studies have shown the role of NOD2 in host protec-
tion against pathogens in a number of bacterial infectious models 
including Listeria monocytogenes (42), Staphylococcus aureus 
(107), Chlamydophila pneumoniae (108), Streptococcus pneumo-
niae (109), and Mycobacterium tuberculosis (110). Nod2-deficient 
mice were susceptible to L. monocytogenes infection via oral but 
not systemic routes, suggesting that NOD2 might have a non-
superfluous role in intestinal antimicrobial responses (11).
The discovery that NOD2 mutations are strongly associated 
with CD highlighted the importance of NOD2 in the regulation 
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of antimicrobial responses. Loss of function mutations in NOD2, 
rendering it unresponsive to peptidoglycan component, MDP, 
have been implicated in the development of CD (41, 111, 112). 
Interestingly, patients with mutant variants of NOD2 have altered 
microbiota in the ileum (32, 33, 113–117). There was a significant 
decrease in the relative frequencies of Clostridia and an increase 
in the Actinobacteria and Proteobacteria in CD patients compared 
to healthy controls (117).
Apart from having role in the bactericidal ability of Paneth 
cells, NOD2 also shapes the microbial community profiles via 
local production of reactive oxygen species (118–120). Adult 
Nod2-deficient mice display a substantially altered microbial 
community structure and a significantly elevated bacterial load 
in their feces and terminal ileum compared to their wild-type 
counterparts (114). Interestingly, these findings were also present 
in weaning-age mice, indicating a subtle influence of NOD2 on 
the early development and composition of the intestinal micro-
biota. Increased load of the Bacteroidetes and Firmicutes phyla as 
well as the genus Bacteroides was observed in the terminal ileum 
of CD patients with homozygosity in NOD2 mutations (114). In 
addition, altered frequencies of Faecalibacterium and Escherichia 
have also been associated with NOD2 risk alleles in CD patients. 
Nod2-deficient mice harbor increased bacterial load in the feces 
and ileum along with increased abundance of Bacteroidetes and 
Firmicutes in comparison to wild-type mice (31, 114, 121). These 
studies are supported by the observations of Petnicki-Ocwieja 
et al., who used the most strict experimental conditions taking 
into account the usage of littermates and bacterial quantifica-
tion by qPCR, with the prominent difference observed only in 
ileum (31).
Several abnormalities in the small-intestinal epithelium 
of Nod2-deficient mice were investigated which included the 
inflammatory gene expression and goblet cell dysfunction (102). 
Ramanan et al. demonstrated that these abnormalities were asso-
ciated with excessive interferon-γ production by intraepithelial 
lymphocytes (IELs) and Myd88-dependent signaling, and were 
dependent on the expansion of a common member of the intesti-
nal microbiota, Bacteroides vulgatus. Although this study implies 
NOD2 prevents harmful immune responses by controlling the 
expansion of a pro-inflammatory member of the microbiota 
(102), the composition of the gut microbiota may vary among 
mice from different laboratories, which may lead to the variations 
in the experimental outcome (31, 114, 121).
NOD2 AND GUT iMMUNe HOMeOSTASiS
The constant exposure of the intestinal tissue to gut microorgan-
isms maintains the mucosa in a state of physiological inflam-
mation, which balances tolerogenic and pro-inflammatory type 
responses to maintain homeostasis. In line with the idea that 
NOD2 signaling might indirectly regulate T cell populations, 
results presented in a recent study indicated that there are 
dysfunctional and reduced numbers of IELs in Nod2-deficient 
mice (122). These effects of NOD2 deficiency could hamper the 
integrity of intestinal epithelium and lead to an altered immune 
response to the resident microbiota. A recent study showed that 
there is an increased sensitivity of Nod2 as well as Rip2-deficient 
mice to DSS-induced colitis and colonic adenocarcinoma as 
a result of dysbiosis, and that the effect can be transmitted to 
wild-type mice through the microbiota (123). However, such 
differences in the composition of gut microbiota as observed in 
naive mice deficient in NOD2 signaling components is debatable 
as many other studies could not arrive at the same conclusion 
(124–126), depicting that, in accordance with the study in 
TLR-deficient mice (127), changes in the relative abundance of 
certain bacterial groups in Nod2-deficient mice emulate caging 
conditions and familial transmission rather than their NOD2 
genotype. In regard to this discrepancy, the question of whether 
NOD2 deficiency can cause different composition of intestinal 
bacteria requires additional study. Likewise, different reports in 
human studies suggest a reduced abundance of certain bacteria, 
including Faecalibacterium prausnitzii and other butyrate-pro-
ducing organisms (128) in patients with colitis, but whether these 
changes occur before the onset of inflammation is an important 
question in the field. Continuing studies, such as these will help 
to determine whether dysbiosis occurs before disease onset and 
whether particular microbial profiles are indeed early biomarkers 
of disease susceptibility.
Studies conducted in healthy SPF mice support the observa-
tion in which failure of NOD2 to induce secretion of antimicro-
bial compounds allows for increase of certain bacterial groups. 
Studies by Petnicki-Ocwieja et al. (31) reported increased loads 
of Bacteroides and Firmicutes groups in the ileum of Nod2-
deficient mice compared to wild-type/heterozygous mice from 
the same litter. However, no such difference was observed in 
the feces of these mice. This observation was attributed to the 
decreased bactericidal activity of crypt-secreted factors, such as 
α-defensins (42). Similarly, increased abundance of Bacteroides 
was also reported in the ileum of Rip2-deficient mice compared 
to wild-type littermates (31). However, Rehman et  al. (114) 
reported immense abundance of Bacteroidetes in the feces of 
adult Nod2-deficient mice, whereas greater load of Firmicutes was 
observed only in the terminal ileum of these mice. Mondot et al. 
(121) reported increased colonic abundance of the Rikenellaceae, 
Bacteroidaceae and Prevotellaceae families in Nod2-deficient 
mice compared to wild-type mice with no specific housing 
conditions. In conclusion, these studies indicate the increased 
bacterial load in the ileum of Nod2-deficient mice although the 
variations observed in these studies can be attributed to different 
housing conditions.
Microbial dysbiosis in CD is likely to be shaped by the chronic 
inflammatory state of the intestine. Abnormal microbial com-
position in association with the detrimental genetic background 
increases the predisposition of Nod2-deficient mice to inflamma-
tory diseases. Several studies on the microbiota in Nod2-deficient 
mice reveal its altered diversity as well as richness (114, 121). 
These studies emphasize the importance of NOD2 in regulat-
ing the intestinal microbiota composition and the subsequent 
outcome of CD.
Previous studies indicate an important role of NOD2 in the 
development of GALT (Gut associated lymphoid tissues) dur-
ing the bacterial colonization of gut (129). In Nod2-deficient 
mice, high proportion of CD4+ T cells, increased inflammatory 
cytokine levels, and higher antigen and bacterial permeability 
7Sidiq et al. NOD2, Ileal Microbiota and Crohn’s Disease
Frontiers in Immunology | www.frontiersin.org September 2016 | Volume 7 | Article 367
rates (124) were observed, indicating an increased stimulation of 
Peyer’s patches (PP) by resident gut microflora. All these changes 
observed in these mice were suppressed after treatment with oral 
antibiotics. Therefore, apart from influencing the development of 
the GALT, NOD2 has a role in modulating the immune response 
by limiting the development of a Th1 immune response toward 
bacteria. The results described above support the observation 
that activation of NOD2 in dendritic cells controls their ability 
to induce a polarized Th1 response in CD4+ T cells (130), thus 
elucidating the role of NOD2 in hematopoietic cells. However, 
this cannot explain why the phenotype of NOD2 mutation is 
only associated with ileal lesion. Also, the Th1 immune response 
phenotype was not observed in other studies unless colonized 
with Helicobacter species (30).
OTHeR POSSiBLe MeCHANiSMS 
CAUSeD BY NOD2 MUTATiONS
Amendola et  al. reported that the absence of spontaneous 
colonic inflammation in Nod2-deficient mice can be attributed 
to altered gut permeability caused by the high mucosal cytokine 
production and increased activity of MLCK. MLCK, myosin 
light chain kinase, is a factor that likely causes the increased gut 
permeability in Nod2-deficient mice due to its effects on tight 
junctions (131). NOD2 deficiency, therefore, causes the perme-
ability changes that increase the exposure of dendritic cells to 
factors, such as TLR ligands that in turn influence Treg cell 
development and subsequent changes in the microbiota. These 
results are in agreement with the studies in IBD patients where 
increased gut permeability and an altered microbiota are associ-
ated with NOD2 polymorphisms with no inflammation (116, 
117, 132, 133). Recently, it was found that NOD2 is expressed 
in Lgr5+ stem cells using culture of intestinal crypt organoids, 
indicating that NOD2 may contribute to epithelial homeostasis 
by regulating stem cell function in addition to bacterial killing 
activity of Paneth cells (134).
Autophagy has emerged as a pivotal component of the innate 
immune response to intracellular bacteria and is also involved in the 
delivery of microbial ligands to intracellular compartments containing 
TLRs to trigger an antimicrobial response. Three groups revealed that 
autophagy is activated by NOD2 to augment intracellular bacterial 
killing (56, 57, 135). The studies by Travassos et al. (57) demonstrated 
that bacterial sensing by NOD proteins is linked to the induction of 
autophagy, thus providing a functional association between NOD2 and 
ATG16L1, two of the most important genes associated with CD. Cooney 
et al. demonstrated that bacterial killing and MHC class II-dependent 
antigen presentation in primary human dendritic cells are increased 
by MDP-activated autophagy and this process involves ATG16L1, 
NOD2, and RIP2, but is independent of NLRP3 (56). Dendritic cells 
from CD patients expressing CD-associated NOD2 or ATG16L1 risk 
variants have the defect in autophagy induction, bacterial trafficking, 
and antigen presentation. Hence, NOD2 polymorphism along with 
the defective lysosomal degradation, and impaired induction of 
antigen-specific CD4+ T cells would lead to bacterial persistence and 
thereby the inflammatory responses in CD (56). Furthermore, a recent 
study showed that ATG16L1- or NOD2-deficient DCs have impaired 
capability to induce Tregs upon stimulation with immunomodulatory 
molecules from the commensal Bacteroides fragilis, indicating the 
immunosuppressive role of NOD2 and ATG16L1 in intestinal den-
dritic cells (136). However, this suppressive function does not explain 
the critical role of NOD2 and ATG16L1 in Paneth cells and ileum 
specific inflammation (137).
Nod2 deficiency in mice, thus, results in increased intestinal bacte-
rial load and greater susceptibility to pathogenic bacterial colonization 
(31), which could result from either Paneth cell dysfunction, defects 
in intestinal autophagic responses, or more likely, a combination of 
the two. Thus, in addition to Paneth cell defects, ATG16L1 and NOD2 
risk variants affect the intestinal epithelial cell antimicrobial responses, 
probably changing the gut microbiome and enhancing CD suscepti-
bility (135).
PeRSPeCTiveS
Although more studies are needed to fully understand the CD 
pathogenesis caused by NOD2 mutations, recent studies have shown 
the important roles of NOD2 in the interactions between microbiota 
and the intestinal immune system. In the studies using Nod2-deficient 
mice, it was shown that NOD2 is critical for the function of bacte-
ricidal activity of ileal crypts and the regulation of ileal microbiota. 
Therefore, it is tempting to speculate that ileal CD caused by NOD2 
mutations is mainly due to the dysfunction of Paneth cells. Under 
physiological condition, microbiota in the ileum is tightly regulated 
by bacterial killing activity of Paneth cells in healthy individuals. This 
regulates both pathogenic and non-pathogenic bacteria as well as 
bacterial antigens that constitutively stimulate the intestinal immune 
system. An increased load of microbiota alone is likely not sufficient 
to induce CD pathogenesis, since inflammatory responses in mucosal 
immunity are tightly regulated by various mechanisms. However, in 
the presence of other genetic, environmental, and immunological 
factors, dysbiosis of bacteria may increase susceptibility to ileal inflam-
mation by enhancing stimulation of the intestinal immune system 
beyond the controlled physiological threshold, leading to pathological 
changes and, finally, to chronic inflammation. Although the studies of 
Paneth cells and microbiota in Nod2-deficient mice and CD patients 
support this scenario, further research is required to fully elucidate the 
molecular mechanism of CD. Additional studies on CD-associated 
microbiota and animal models of ileal CD may provide a greater 
insight to develop better treatment and management methods of CD 
patients.
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